Stockscreener 앱 받기
0.7125
9.42%
-0.0679
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte Financial Disclosures & SEC Filings - TradingView
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Yahoo! Finance Canada
Humacyte Announces $50 Million Public Offering of Common Stock - Global Legal Chronicle
HUMA stock plunges after-hours on proposed share offering even as dialysis data impresses - MSN
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market - MSN
Enterprise value to revenue forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data - Yahoo Finance
Price to earnings forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Humacyte, Inc. (HUMA) latest stock news and headlines - Yahoo Finance Singapore
Price to book forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Price to sales forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Enterprise value to revenue forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Humacyte, Inc. Actuals & Estimates (NASDAQ:HUMA) - TradingView
Enterprise value to EBITDA forward of Humacyte, Inc. – BOATS:HUMA - TradingView
HUMA Forecast — Price Target — Prediction for 2027 - TradingView
Humacyte Inc (HUMAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Humacyte Inc (HUMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
Form 13G Humacyte For: 22 June By Investing.com - Investing.com South Africa
Davidson Kempner reports 4.74% stake in Humacyte (NASDAQ: HUMA) - Stock Titan
Humacyte Inc (HUMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - Yahoo Finance
Humacyte, Inc. (HUMA) dips more than broader market: What you should know - MSN
Piper Sandler Maintains Humacyte(HUMA.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Humacyte Inc (HUMAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Qiagen (QGEN) - The Globe and Mail
Humacyte Inc (HUMAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Humacyte Inc (HUMA) Institutional Confidence - TradingKey
Humacyte Inc (HUMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Humacyte Inc (HUMA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Humacyte Inc (HUMA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Humacyte Inc (HUMAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Humacyte Inc (HUMAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Humacyte Inc (HUMAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Humacyte Inc (HUMAW) Institutional Confidence - TradingKey
Humacyte Inc (HUMAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Humacyte Inc (HUMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Humacyte Inc (HUMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Humacyte Inc (HUMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
HUMA Maintained by TD Cowen -- Price Target Lowered to $1.25 - GuruFocus
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know - Yahoo Finance
HUMA Reiterates by BTIG -- Price Target Maintained at $2.00 - GuruFocus
Humacyte (HUMA) Barclays 28th Annual Global Healthcare Conference Summary - Quartr
Humacyte, Inc. (HUMA) surpasses market returns: Some facts worth knowing - MSN
Humacyte (NASDAQ:HUMA) reports positive Phase 3 V012 trial results - grafa.com
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Humacyte stock rises on positive dialysis trial results By Investing.com - Investing.com India
Humacyte stock rises on positive dialysis trial results - Investing.com
Fresenius updates 6.8% Humacyte (HUMA) ownership stake disclosure - Stock Titan
Humacyte’s bioengineered vessel shows benefit for women on dialysis - Investing.com UK
Humacyte’s bioengineered vessel shows benefit for women on dialysis By Investing.com - Investing.com Nigeria
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting - The Manila Times
Bioengineered blood vessel helps women on dialysis avoid catheters longer - Stock Titan
Number of shareholders of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
0.44%
1.59%
자본화:
|
볼륨(24시간):